iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($)					1 Months Ended	3 Months Ended		12 Months Ended
Basis of Presentation (Details) - USD ($)	Oct. 29, 2019	Jul. 12, 2018	Jun. 26, 2018	Nov. 30, 2017	Nov. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 20, 2018
Basis of Presentation [Line Items]
Accumulated deficit						$ (110,284,000)		$ (105,821,000)
Net Cash Used in Operating Activities						(2,287,000)	$ (778,000)
Cash						2,103,000	8,164,000	4,421,000	$ 8,088,000
Net proceeds from underwritten public offering	$ 4,515,000
Stock Issued During Period, Shares, New Issues			4,350,000	2,250,000
Stock Issued During Period, Value, New Issues			$ 16,000,000	$ 4,500,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest						(4,464,000)	(4,399,000)
Shares Issued, Price Per Share				$ 2.00
Contract liabilities						2,894,000		1,279,000
Contract with Customer, Liability							$ 2,900,000
Contract with Customer, Liability, Revenue Recognized						47,205		$ 1,800,000
Proceeds from Contributed Capital					$ 2,459,000
Conversion of Series C Preferred Stock into common stock, conversion price per share	$ 0.20
Master Manufacturing Services and Supply Agreement ("MSA") \| Lung Bio
Basis of Presentation [Line Items]
Advance received						1,600,000
Purchase of capital expenditure						1,000,000
Related contracted services						620,000
Contract liabilities						1,600,000
Contract with Customer, Liability, Revenue Recognized						46,000
Over-Allotment Option [Member]
Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock		$ 1,350,000
Stock Issued During Period, Shares, New Issues		1,500,000
Stock Issued During Period, Value, New Issues		$ 1,350,000
Shares Issued, Price Per Share		$ 0.90
Common Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			4,350,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest						$ 0
Shares Issued, Price Per Share			$ 0.90							$ 0.90
Series A Preferred Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			6,300
Preferred Stock, Par or Stated Value Per Share			$ 1,000							0.001
Convertible Preferred Stock, Shares Issued upon Conversion			7,000,000
Convertible Preferred Stock Conversion Price			$ 0.90
Conversion of Series C Preferred Stock into common stock, conversion price per share						$ 0.20
Preferred stock, par value (in dollars per share)			$ 1,000							0.001
Series B Preferred Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			5,785
Shares Issued, Price Per Share	$ 0.20		$ 0.90							0.90
Preferred Stock, Par or Stated Value Per Share			$ 1,000							0.001
Convertible Preferred Stock, Shares Issued upon Conversion			6,427,778
Conversion of Series C Preferred Stock into common stock, conversion price per share						$ 0.20
Preferred stock, par value (in dollars per share)			$ 1,000							$ 0.001
Subsequent Event [Member]
Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock	$ 4,520,000
Subsequent Event [Member] \| Underwritten Public Offering [Member]
Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock	$ 5,000,000
Subsequent Event [Member] \| Common Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues	2,450,000
Shares Issued, Price Per Share	$ 0.001